现任执委会成员

Members of the Board of Directors (BoD):

Four BoD and Executive Council Members:

President: Prof. Monique Simmonds

I gained my BSc at Leeds University and PhD from Birkbeck College, University of London. I joined Royal Botanic Gardens, Kew in 1985 working on different aspects of plant/fungal chemistry. I was introduced to Traditional Chinese Medicine in the mid 1990’s by my colleague Dr Christine Leon. I then helped Kew raise funds for the creation of the large collection of TCM at Kew that started in 1998. I was then involved in a range of TCM related projects and was part of the team headed by Dr Qihe Xu (Kings College) that summited the EU-China F7 Network Proposal that was the initial concept for this society. I initially headed the Quality Control Work-package. I have taken an active role in different aspects of the quality control of herbs and was invited to join the International Advisory Committee Materia Medica, Hong Kong and I chair the Herbal Advisory Committee for the UK Pharmacopeia Committee. I work with Prof Clara Lau on joint projects and have academic and commercially funded projects on TCM plants in China. I have over 350 scientific publication. I was awarded an OBE (UK honour) for services to science, the environment, technological innovation and community.

Return to top

Past President: Prof. Aiping Lu

Aiping Lu

Professor Lu Aiping is Chair Professor & Dean of School of Chinese Medicine, Hong Kong Baptist University, and Chair Professor in Shanghai University of Traditional Chinese Medicine. Prof. Lu is also the recipient of the Distinguished Young Scholar in National Science Foundation of China (NSFC) in 2007. Besides, he also as Member of Medical Advisory Committee of National Natural Science Foundation of China (NSFC), Member of Chinese Pharmacopoeia Commission and Vice-Chairman, Terminology of Traditional Chinese Medicine Sub-Committee, China National Committee for Terms in Sciences and Technologies (CNCTST). Also he has been appointed as Head & Spokesperson of the China Delegation, International Organization for Standardization Technical Committee on TCM (ISO/TC249) since 2009. His research interests mainly focus on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with traditional Chinese medicine pattern diagnosis and interventions, and development of new drugs based on Chinese medicines. Also he is actively involving the research on the standardization of Chinese medicine and strategic plan research for Chinese medicine development in China. Prof Lu has published more than 30 books and over 500 articles, including 200 articles in SCI journals such as Nature Medicine, Nature Communication, Biomaterials, and Briefings in Bioinformatics.

Return to top

Secretary-General and President-Elect:

Prof. Clara Bik-San Lau

Professor Clara Lau is currently the Associate Director of the Institute of Chinese Medicine and the State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants at The Chinese University of Hong Kong. She also has a courtesy appointment as Associate Professor at the School of Chinese Medicine, CUHK. With BPharm and PhD in Pharmacy (Pharmacognosy) from King’s College London, University of London, UK, she has a continuous interest in both western herbals and traditional Chinese medicines (TCM), and has over 26 years’ experience in Pharmacognosy and herbal/natural products research, focusing on anti-cancer natural products and beneficial herb-drug interaction. She has published over 250 SCI journal articles and 8 book chapters, and has successfully supervised/co-supervised 12 postdoctoral fellows and 35 MPhil/PhD postgraduates in Chinese Medicine, Pharmacognosy or Biochemistry. Currently, she serves as member of ChP-USP Advisory Group on Monographs for TCM Ingredients and Products; Acting Secretary-General of The Consortium for Globalization of Chinese Medicine (CGCM); Secretary-General of Good Practice in Traditional Chinese Medicine Research Association (GP-TCM RA); Council member and Associate Chief Executive of Modernized Chinese Medicine International Association (MCMIA); Associate Editor of “Journal of Traditional and Complementary Medicine (eJTCM)”, Consulting Editor of “Pharmacological Research”, and Editorial Board member of journals “Phytomedicine”, “Scientific Reports”, “Journal of Natural Products”, “Journal of Ethnopharmacology” and “Journal of Pharmacy and Pharmacology”.

Return to top

Treasurer: Dr. Tai-Ping Fan

Trained in immunopharmacology, Dr Tai-Ping Fan has worked at Cambridge University for more than 30 years aiming to develop safe, effective and affordable phyto-pharmaceuticals from TCM and other ethnic medicines.

With his collaborators in Xi’an, Wuxi and Jinan, they have developed Jun-Shi Medicinal Compatibility Model for discovering and patenting pro-angiogenic, anti-convulsant and anti-hypertensive compounds, and elucidating their molecular mechanisms of action.  Recently, they have developed engineered E. coli and cell-free biosynthetic approaches to generate natural products of therapeutic value; established a comprehensive zebrafish-based platform for evaluation of bio-activities and toxicity of natural and synthetic chemicals.

In 2017, he was instrumental in convincing the Czech Chamber of Deputies to incorporate TCM into the Czech healthcare system.  In response to the COVID-19 outbreak, Dr Fan has collaborated with a Chinese biotech company and used its patented Plant Low-temperature Extraction & Efficient Separation Integration Technology to eliminate heavy metals and pesticide residues and to produce high-quality herbal granules from established TCM formulations for the prevention and treatment of coronavirus infection.

In addition to prestigious professorships in universities and research associateships in research institutes, Dr Fan was honoured with the 2019 Qihuang International Prize from China Association of Chinese Medicine.

 

Return to top

Thirteen BoD Members (in alphabetical order):

Prof. Rudolf Bauer

Studied pharmacy at University of Munich; Ph.D. in 1984; 1993-2002 associate professor at the Institute of Pharmaceutical Biology, University of Düsseldorf; since 2002 professor of pharmacognosy at University of Graz, Austria; 2004 – 2020 Head of Institute of Pharmaceutical Sciences at University of Graz, now Deputy Head; since 2008 head of TCM Research Center Graz – medicinal plant research. Guest professor at School of Chinese Materia Medica, Beijing University of Chinese Medicine; Guangxi Botanical Garden of Medicinal Plants and Institute of Guangxi Medicinal Plants, Nanning; Institute of Medicinal Plant Development, China Academy of Medical Sciences, Beijing; Chengdu University of TCM; Heilongjiang University of CM, Harbin; Changchun University of CM. Recipient of Egon-Stahl-Award of the Society for Medicinal Plant Research (GA); Norman Farnsworth Excellence in Botanical Research Award; Qihuang International Prize of China Association of Chinese Medicine, Outstanding International Scientist Award (Pranab Banerji Memorial Award) of the Society for Ethnopharmacology India (SFE). Honorary doctorate of University of Helsinki.

Associate Editor in Chief of Chinese Journal of Natural Medicines and World Journal of Traditional Chinese Medicine (WJTCM). Chairman of the expert group on Chinese herbs of the European Pharmacopoeia. Previous president of the Society for Medicinal Plant and Natural Products Research (GA) and of the International Society for Ethnopharmacology (ISE). Long experience in natural product chemistry; ca. 390 scientific publications.

Return to top

Mr. Abraham Chan

Abraham Chan

I am the founder and Chairman of PuraPharm Corporation Ltd, a publicly traded company listed on the Main Board of HK Stock Exchange. PuraPharm dedicates itself to the modernization and internationalization of traditional Chinese medicine (TCM) and is a leading company engaged in the R&D, production, marketing and selling of concentrated Chinese Medicine granules(CCMG) products.PuraPharm has been supplying CCMG to the majority of hospitals in Hong Kong since 2004 and is one of the only five, and the only non-PRC company licensed by the CFDA to manufacture and sell CCMG products in China.  PuraPharm is the largest and the leading CCMG manufacturer in Hong Kong, and owns the largest Chinese medicine clinic chain in HK. PuraPharm’s own TCM research & production facilities is based in Guangxi, China which complies with the PRC Good Manufacturing Practice (GMP) standards, as well as Australia’s Therapeutic Goods Administration (TGA) standards. PuraPharm also owns a Chinese herbs plantation site in the province of Guizhou, China, covering an area of over 4,000 acres.

As the founder and the Chairman of the Company and with extensive experience in Chinese medicine and healthcare products, I am responsible for directing the overall strategies and planning of the Group’s business. I also lead the Group’s R&D and technological development functions.  PuraPharm, actively collaborating with various universities and research institutes internationally, has established itself as the technological front-runner within the industry.  Through continuous innovation, PuraPharm has come to be regarded as a leading company in the research and development of traditional Chinese medicine.

Return to top

Prof. Pierre Duez

PhD in Pharmaceutical Sciences (Toxicology), Pierre Duez heads a teaching and research department in the Université de Mons (Faculty of Medicine and Pharmacy); he is teaching Pharmacognosy, Pharmacology, Nutrition and bibliographical tools, both in theory and practice. He has access to chromatographic and spectroscopic techniques for Belgian and foreign PhD students. Specialized in the study and analysis of natural products, the team concentrates on the elucidation of DNA repair modulators and on the integration of traditional medicines with African modern medicine (DR Congo). Pierre Duez is member of the European Pharmacopoeia TCM working party, of the European Medicines Agency (Monograph and List Working Party), of the Belgian Commissions of Pharmacopoeia and Registration of Herbal Medicines. He is active in development cooperation with Algeria, Argentina, Burkina Faso, Ecuador, Uganda, DR Congo, PR China (Macao), Rwanda, Madagascar, Vietnam. Member of the GP-TCM consortium, he is currently Board Member and Chair of the Pharmacology & Toxicology Interest Group for the GP-TCM RA.  He is (co-)supervisor of 21 defended theses, co-editor of 1 book, co-author of 10 book chapters, 169 scientific papers, 1 report for the European Development Fund, 1 patent and 328 communications in meetings. He has organized the 2015 GP-TCM RA meeting in Mons, Belgium.

Return to top

Prof. Thomas Efferth

Professor Dr. Prof. h. c. mult. Thomas Efferth is chair of the Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany. He is biologist by training (Technical University of Darmstadt, Germany). Doctoral thesis: German Cancer Research Center (DKFZ), Heidelberg, Germany (1990). Awards: Prize of the Southwest German Association for Medicine (1991), Willmar-Schwabe-Award of the German Society for Medicinal Plant Research (2006), citizen medal of the City of Heidelberg, Germany (2008), CESAR Award for Translational Oncology (2011), SCENTEDdrop Award on medicinal and flagrant herbs (2015), Qihuang International Award of the Chinese Association of Chinese Medicine (2017). Since 2018, he is full member of the World Academy of Sciences. He headed a research group for Pharmaceutical Biology at DKFZ (2005-2009) and was adjunct professor (apl.) at the University of Heidelberg (2007-2009). In 2009, he took over the Chair of Pharmaceutical Biology (full professorship) at the Johannes Gutenberg University, Mainz. Furthermore, he is honorary professor at the Northeast Forestry University, Harbin, and at the Zhejiang Chinese Medical University, Hangzhou, China. Moreover, he is visiting professor at the Zhejiang University of Science and Technology, Hangzhou, China and honorary adjunct professor at the Chinese University Hong Kong.

Thomas Efferth published 650 PubMed-listed papers and in peer-reviewed journals in the field of cancer research, pharmacology, and natural products (Hirsch-factor: 82; citation rate: 30,000; acc. Google Scholar) and a textbook on ‘Molecular Pharmacology and Toxicology’ (Springer Publisher; 2006). He holds 7 patents. The scientific results were communicated in over 270 oral presentation and invited lectures and over 200 poster presentations at national and international conferences and meetings. He is editor-in-chief of Phytomedicine and Phytomedicine Plus as well as associate editor of several other scientific journals and scientific advisory board member (e.g. German Pharmaceutical Society, Hong Kong Research Grant council etc.). Thirteen of his former lab members promoted to leading academic positions (1 president, 2 full professors, 10 associate/assistant professors). The focus of Dr. Efferth’s research is on tumor pharmacology, network pharmacology, and recently also on COVID-19.

Return to top

Prof. Rong-Rong He

Professor Rong-Rong He is the Director of Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility in Jinan University, Guangzhou, China. She also serves as the Vice Dean of TCM College and Associate Director in the Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University. She gained her Pharm and PhD in Pharmacy (Chinese Materia Medica) from Shenyang Pharmaceutical University, Shenyang, China. The effectiveness of herbal medicine has always been difficult to evaluate with conventional pharmacological methods. To tackle these problems, she focuses on using a variety of stress-loaded models for anti-stress research and natural product evaluations and improving their effectiveness on homeostasis and disease prevention. This series of novel research projects are supported by dozens of funding sources such as National Natural Science Foundation. As a young researcher, she has published over 100 scientific articles in peer reviewed journals, presented scientific reports in local, national and international conferences, and is the owner of 6 authorized patents. In 2019, Dr. He has been awarded with the Guangdong Provincial Science and Technology Progress Award (First Class) and Technological Progress Award from Ministry of Education (Second Class) for her original contributions for the TCM studies.

Return to top

Prof. Simon Ming-Yuen Lee

Prof. Simon Lee is currently Distinguished Professor (Biomedical Science), State Key Laboratory of Quality Research in Chinese medicine of the Institute of Chinese Medical Sciences and also Department of Pharmacological Science of the Faculty of Health Science, at the University of Macau. Simon obtained PhD degree in biochemistry from The Chinese University of Hong Kong. His research interests lie in the discovery of drug-like agents from natural products including small molecule and biologics for use in various therapeutic areas, including neurodegenerative and cerebrovascular diseases. He also developed cutting-edge drug screening technologies, including genomics and zebrafish disease models, which have made an impact in terms of the discovery of new therapeutic agents from natural products. His dedication to education and research in the fields of pharmacology and toxicology has leaded to over 300 scholarly articles, including Nature Communications (4×), and over ten granted patents.

Simon is a life member of Clare Hall, University of Cambridge and has been granted honorary professorship by various universities around the world (e.g. Peking University, The University of Hong Kong, and The Baptist University of Hong Kong). He has served as a committee member for different professional associations (Chair of Council, Macau Pharmacology Association; Executive President, Consortium of ‘Belt and Road’ and Portuguese-Speaking Countries for Natural Medicine Innovation (Macao); Committee Member of Neuropsychopharmacology, and Committee Member of Pharmacology on Traditional Chinese Medicine and Natural Medicine, Chinese Pharmacological Society; Cooperation Partner, WHO Collaborating Centre for Traditional MedicineHealth Bureau of Macao SAR government; Technical Expert of Accreditation Assessment for the Innovation and Technology Commission of Hong Kong SAR government).

 

Return to top

Prof. Nicola Robinson

Nicola Robinson is Emeritus Professor of Traditional Chinese Medicine and Integrated Health, London South Bank University, UK. Having obtained a PhD in immunology at Manchester University she became a registered acupuncturist in 1982 and awarded Fellowship of the British Acupuncture Council (BAcC) in 2008. In 2004, Nicola was awarded a Winston Churchill Traveling Fellowship to visit China, for 8 weeks, exploring educational and research initiatives in TCM and began her collaboration with Chinese academics. As well as TCM, she also has considerable research experience in public health and health services research.  She is Editor in Chief of the European Journal of Integrative Medicine (Elsevier) and on the board of 5 Chinese academic journals. Nicola has written over 200 scientific articles in peer reviewed journals and presented internationally. She has successfully supervised Chinese and UK PhD and postdoctoral students. Her research has included many topics using different methodologies with the aim of highlighting the importance of integrated medicine including; stroke, muscular skeletal pain, phantom limb pain, osteoarthritis of the knee, post marketing surveillance of herbal injections and clinical guidelines. In 2018, she was honoured to be awarded the role of visiting overseas master professor role by the Ministry of Education of the People’s Republic of China at the Centre for Evidence Based Chinese Medicine at Beijing University of Chinese Medicine.

Return to top

Dr. Lee-Yan Sheen

Dr. Lee-Yan Sheen is the Distinguished Professor at Institute of Food Science and Technology, National Taiwan University (NTU), Taiwan and the Director of Center for Food and Biomolecules as well as the Director of National Center for Food Safety Education and Research, NTU. He also serves as the President, International Association for Traditional and Complementary Medicine (IATCM) and Founding and Honorary President of Taiwan Association for Traditional and Complementary Medicine (TATCM) as well as the Founding and Honorary President of Taiwan Association for Food Protection (TAFP). In addition, he is the Editor-in-Chief of Journal of Traditional and Complementary Medicine (JTCM). Dr. Sheen completed his Ph.D. from the Department of Food Science, National Chung-Hsing University, Taiwan. His Ph.D. graduate program included the National scholarship supported by Taiwan government for one-year study in the Department of Food Science, Rutgers University, USA (1989-1990). He holds M.S. and B.S. from the Department of Food Science, National Chung-Hsing University, Taiwan. The name of Dr. Sheen’s lab is “Lab of Dietary Therapy” and his research includes physiological functions of foods (such as using natural ingredients and herbs for the health promotion and preventive medicine of anti-depression, cancer prevention, and anti-oxidation and detoxification systems in liver as well as gut microbiota), food safety, traditional Chinese dietary therapy. He is much involved in the regulation and policy decision making processes and very active in the food industry and health medicine-related applications in Taiwan. He holds numerous awards and honors; authors and co-authors more than 50 publications in the recent five years.

At present, Chinese medicine is no longer for clinical diseases only. The paradigm of medicine has changed from disease to healthcare. The scope of medicine includes uses for disease treatment (therapeutic medicine), disease prevention (preventive medicine), and life quality enhancement of healthy individuals and patients (functional medicine). Dr. Sheen is doing his best to promote complementary therapy on neurodegenerative diseases.

Return to top

Prof. Helen Sheridan

I am a founding and life member of the GP-TCM; Academic Director and Founder, of NatPro the TCD Centre for Natural Product Research (2019) at Trinity College Dublin (TCD); former Director of Research at the School of Pharmacy (2016-19). I was elected to fellowship at TCD (FTCD; 2020); awarded the Provost’s Teaching Award (2019); Elected to Fellowship of the Royal Society of Chemistry (2016). I Founded Trino Therapeutics Ltd – A TCD Spin-out (2000) in drug discovery. My research is the area of natural product inspired drug discovery. I have brought one molecule to Phase 1 human trials through the MHRA. I have secured €19,697,672 research funding: from National, international, Venture and Philanthropic funding, including a prestigious Wellcome Trust Translation Award (€3M co-PI). I was recently awarded €6M in Philanthropic funding from the Department of Justice/ IIP programme from Chinese Investors “Kylin Prime Group”, for a Natural Product project looking for commercial or therapeutic discoveries form the bogs of Ireland. I am the phytochemical expert to the National Health Products Regulatory Authority (HPRA) (2000-to date). I have 89 peer reviewed publications including 7 international patents in drug discovery. I worked Part time >25 years due to a chronic medical condition.

Return to top

Dr. Mei Wang

Dr. Mei Wang, founder and chairperson of LU-European Center for Chinese Medicine and Natural compounds (LUECCM), Institute of Biology, Leiden University,, Netherlands, expert member and representative of Dutch pharmacopeia for TCM working party at European pharmacopeia committee EDQM, vice-chair of the World Federation of Chinese Medicine (WFCMS) Specialty Committee of innovative natural medicine, board member of NVF (Dutch association of Phytotherapy, member of ESCOP), associate editor of the journal Phytomedicine.

She holds a PhD (1988) in cell biology and genetics from Leiden University, Netherlands and a BSc (1982) from Peking University, P.R. China. Based on a huge science and business success in the field of secondary plant metabolites in animal (and human) systems, she formed a Plant Systems Biology group linked with TNO Systems Biology Technology platform and Leiden University Pharmacognosy Research group. From this activity onwards the innovative strategy on bridging Western and Eastern medicine based on TCM and the company SUBiomedicine was established in 2004. She is the CEO of SUBiomedcine. SUBiomdicine has realized, as the first company in the world, the registration of a Chinese medicine product according to tHMP (traditional Herbal medicinal product) rules in Europe that is produced in China. In 2018, she obtained the international “Qihuang prize’ which was awarded by Chinese Medicine Society.

Return to top

Prof. Xuanbin Wang

Prof. Xuanbin Wang, PhD, Director of Hubei Key Laboratory of Wudang Local Chinese Medicine Research (KLWDCM), Deputy Director of Biomedical Research Institute, and Director of Laboratory of Chinese Herbal Pharmacology, Renmin Hospital in Hubei University of Medicine (HBMU), China. I graduated from Huazhong University of Science and Technology (HUST) and obtained my PhD degree in 2009. Then I started my academic career focusing on Chinese herbal pharmacology including Taoist medicine — unique Han folk medicine. In 2011-2013, I worked in School of Pharmacy, the University of Hong Kong (HKU) as a research assistant under Prof. Yibin Feng. In 2018, I was a visiting scholar in LMU Grosshadern Hospital Munich co-working with Dr. Minglun Li, Vice-Director of Department of Radiation Oncology. In August 2019, I was elected as the Vice-President of Chinese Experimental Pharmacology Branch of China Association of Chinese Medicine (CEPBCACM) (Chairman: Prof. Hongxi Xu). My main research interest is ant-cancer Chinese medicines (including Taoist medicine). In July 2017, I became a Life Member of GP-TCM RA. I have attended the 6th and 7th GP-TCM RA annual meetings in London and Deagu. Under the instruction by Dr. Qihe Xu, I had been editing our newsletters as a Vice Editor in-Chief.

Return to top

Prof. Vivian Taam Wong

Current Service to Professional Organizations:

  • Hon Professor, School of Chinese Medicine, HKU
  • Vice President, Modernized Chinese Medicine International Association
  • Board of Director, GP-TCM Research Association
  • HK Coordinator, Consortium for Globalization of Chinese Medicine
  • Council Member, Chinese Association of Integrative Medicine
  • Member, International Chinese Medicine Clinical Standards Working Committee, WFCMS

Key Past Appointments:

  • Public Health Specialist, Policy & Research, World Bank
  • Chairman, Committee on Safe Motherhood, International Federation of Gynecology & Obstetrics
  • Consultant on various Committees under WHO
  • Consultant on Health Project IV & VI in China for World Bank
  • Chief Executive, Queen Mary Hospital & Hospital Authority, HK
  • Hon Advisor in Integrative Medicine, Hospital Authority, HK
  • Hon Senior Advisor on Chinese Medicine, Medical Faculty, HKU

She has been on editorial boards of 7 journals, and published >130 peer-reviewed papers.  She set up the unique HK-wide Research Ethics Committee system & standards enabling multicentre trials as well as the high quality network of Chinese Medicine Centres for Training and Research in each district in HK.  While steering education, research and knowledge transfer in integrative medicine, she has fostered collaboration among the Government, industry, Universities and researchers to plan a “Greater Bay Area CM Innovation and Trading Park”.

Return to top

Dr. Qihe Xu

Dr. Qihe Xu, MD and PhD, Senior Lecturer in Renal Medicine & Integrative Chinese Medicine, Director of the King’s Centre for Integrative Chinese Medicine (CICM) initiative, and Organiser of MSc Pharmacology Projects at King’s College London (KCL).

After a decade of medical practice in Beijing, I started an academic career in London in 1999. I used to be Secretary-General, Chinese Students & Scholars Association in the UK, and President, Chinese Life Scientists Society in the UK.

In 2009-2012, I was the PI of the FP7 GP-TCM Project, which founded the GP-TCM RA. As a GP-TCM RA Life Member, I have served on the BoD for three terms. I was Vice-President (2012-2014), Newsletter Editor-in-chief (2017-2019), and am Newsletter Consulting Editor and Associate Editor-in-chief, WJTCM, official journal of the Association.

I am passionate about integrating TCM wisdom into tomorrow’s medicine and pharmacology and my research focuses on TCM-inspired studies of kidney health and disease, herbal antifibrotics and botanical nephrotoxicity. Lately, I’m honoured to be nominated for the 2020 Qihuang International Prize, China Association of Chinese Medicine.

Return to top

Comments are closed.